Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

The Biogened S.A. (WSE:BGD) share price has fared very poorly over the last month, falling by a substantial 37%. Looking back over the past twelve months the stock has been a solid performer regardless, with a gain of 16%.

Following the heavy fall in price, given about half the companies in Poland have price-to-earnings ratios (or "P/E's") above 13x, you may consider Biogened as an attractive investment with its 9x P/E ratio. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's limited.

The earnings growth achieved at Biogened over the last year would be more than acceptable for most companies. One possibility is that the P/E is low because investors think this respectable earnings growth might actually underperform the broader market in the near future. If that doesn't eventuate, then existing shareholders have reason to be optimistic about the future direction of the share price.

View our latest analysis for Biogened

We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on Biogened's earnings, revenue and cash flow.

What Are Growth Metrics Telling Us About The Low P/E?

Biogened's P/E ratio would be typical for a company that's only expected to deliver limited growth, and importantly, perform worse than the market.

Taking a look back first, we see that the company grew earnings per share by an impressive 24% last year. The strong recent performance means it was also able to grow EPS by 222% in total over the last three years. Therefore, it's fair to say the earnings growth recently has been superb for the company.

This is in contrast to the rest of the market, which is expected to grow by 5.7% over the next year, materially lower than the company's recent medium-term annualised growth rates.

With this information, we find it odd that Biogened is trading at a P/E lower than the market. It looks like most investors are not convinced the company can maintain its recent growth rates.

What We Can Learn From Biogened's P/E?

The softening of Biogened's shares means its P/E is now sitting at a pretty low level. While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.

We've established that Biogened currently trades on a much lower than expected P/E since its recent three-year growth is higher than the wider market forecast. When we see strong earnings with faster-than-market growth, we assume potential risks are what might be placing significant pressure on the P/E ratio. It appears many are indeed anticipating earnings instability, because the persistence of these recent medium-term conditions would normally provide a boost to the share price.

And what about other risks? Every company has them, and we've spotted 4 warning signs for Biogened (of which 1 shouldn't be ignored!) you should know about.

If these risks are making you reconsider your opinion on Biogened, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.